Sutro Biopharma, Inc.
STROHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframeSutro Biopharma, Inc. operates as an oncology company. The company carries a $332.8M market cap, placing it firmly in the small-cap category. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+.
Market Cap
$332.8M
Beta
1.49
P/E (TTM)
—
P/E (Fwd)
-3.23
EPS (TTM)
$-17.38
EPS (Fwd)
$-6.21
ROE
—
ROA
-36.1%
Cash
$164.3M
Total Debt
$10.8M
Free CF
-$100.8M
52W Change
104.8%
Annual Financials
Cash vs Debt
Where STRO stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, STRO finished 21.70% below its 150-day moving average ($25.85) and 8.08% below its 200-day moving average ($22.02). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is STRO overbought or oversold?
At the September 1, 2026 close, STRO's RSI(14) was 26.7, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $164.3M in cash and $10.8M in debt, STRO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$100.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $67.8M (2022) to $102.5M (2025), reflecting a 51% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Sutro Biopharma, Inc. and its sector.